BACKGROUND Sepsis is a severe illness characterized by systemic and multiorgan reactive responses and damage.However,the impact of sepsis on the bone marrow,particularly on bone marrow mesenchymal stem cells(BMSCs),is less reported.BMSCs are critical stromal cells in the bone marrow microenvironment that maintain bone stability and hematopoietic homeostasis;however,the impairment caused by sepsis remains unknown.AIM To investigate the effects of sepsis on BMSCs and the underlying mechanisms.METHODS BMSCs were obtained from healthy donors and patients with sepsis.We compared the self-renewal capacity,differentiation potential,and hematopoietic supportive ability in vitro.Senescence of septic BMSCs was assessed usingβ-galactosidase staining,senescence-associated secretory phenotype,intracellular reactive oxygen species levels,and the expression of P16 and P21.Finally,the changes in septic BMSCs after nicotinamide adenine dinucleotide(NAD)treatment were evaluated.RESULTS Septic BMSCs showed decreased proliferation and self-renewal,bias towards adipogenic differentiation,and weakened osteogenic differentiation.Additionally,hematopoietic supportive capacity declines in sepsis.The levels of aging markers were significantly higher in the septic BMSCs.After NAD treatment,the proliferation capacity of septic BMSCs showed a recovery trend,with increased osteogenic and hematopoietic supportive capacities.Sepsis resulted in decreased expression of sirtuin 3(SIRT3)in BMSCs,whereas NAD treatment restored SIRT3 expression,enhanced superoxide dismutase enzyme activity,reduced intracellular reactive oxygen species levels,maintained mitochondrial stability and function,and ultimately rejuvenated septic BMSCs.CONCLUSION Sepsis accelerates the aging of BMSCs,as evidenced by a decline in self-renewal and osteogenic capabilities,as well as weakened hematopoietic support functions.These deficiencies can be effectively reversed via the NAD/SIRT3/superoxide dismutase pathway.
BACKGROUND Periodontitis is an inflammatory disease caused by the host’s immune response and various interactions between pathogens,which lead to the loss of connective tissue and bone.In recent years,mesenchymal stem cell(SC)transplantation technology has become a research hotspot,which can form periodontal ligament,cementum,and alveolar bone through proliferation and differentiation.AIM To elucidate the regulatory effects of WD repeat-containing protein 36(WDR36)on the senescence,migration,and osteogenic differentiation of periodontal ligament SCs(PDLSCs).METHODS The migration and chemotaxis of PDLSCs were detected by the scratch-wound migration test and transwell chemotaxis test.Alkaline phosphatase(ALP)activity,Alizarin red staining,calcium content,and real-time reverse transcription polymerase chain reaction(RT-qPCR)of key transcription factors were used to detect the osteogenic differentiation function of PDLSCs.Cell senescence was determined by senescence-associatedβ-galactosidase staining.RESULTS The 24-hour and 48-hour scratch-wound migration test and 48-hour transwell chemotaxis test showed that overexpression of WDR36 inhibited the migration/chemotaxis of PDLSCs.Simultaneously,WDR36 depletion promoted the migration/chemotaxis of PDLSCs.The results of ALP activity,Alizarin red staining,calcium content,and RTqPCR showed that overexpression of WDR36 inhibited the osteogenic differentiation of PDLSCs,and WDR36 depletion promoted the osteogenic differentiation of PDLSCs.Senescence-associatedβ-galactosidase staining showed that 0.1μg/mL icariin(ICA)and overexpression of WDR36 inhibited the senescence of PDLSCs,and WDR36 depletion promoted the osteogenic differentiation of PDLSCs.CONCLUSION WDR36 inhibits the migration and chemotaxis,osteogenic differentiation,and senescence of PDLSCs;0.1μg/mL ICA inhibits the senescence of PDLSCs.Therefore,WDR36 might serve as a target for periodontal tissue regeneration and the treatment of periodontitis.
Yi WangFeng-Qiu ZhangZhi-Peng FanXin-Ling ZhuWan-Hao YanXiu-Li Zhang
In an article published in Cell in September 2024,Baldwin and colleagues present a bone marrow stromal cell(BMSC)based mitochondrial transfer platform to combat mitochondrial dysfunction or scarcity in human T cells ex-vivo.1 This thorough and methodically diverse investigation results in a promising technology at a time when adoptive T cell therapies seem to run against a wall of T cell exhaustion and dysfunction in treatments targeting solid tumors.
Lars Fabian PrinzRoland Tillmann UllrichMarkus Martin Chmielewski
